Aurora Cannabis Provides Construction Update on Aurora Sun Facility Footprint Increased to 1.6 Million Square Feet, Target Capacity 230,000+ kg per Annum Next Generation Technology Systems to Result in Further Reduced Pr

Aurora Cannabis Provides Construction

Update on Aurora Sun

Facility Footprint Increased

to 1.6 Million Square Feet, Target Capacity 230,000+ kg per Annum

Next Generation Technology

Systems to Result in Further Reduced Production Costs

EDMONTON, April 10, 2019 /CNW/ - Aurora

Cannabis Inc. (the "Company" or "Aurora") (NYSE: ACB) (TSX: ACB) (Frankfurt: 21P; WKN: A1C4WM) today announced

an update on the status of Aurora Sun, the Company's latest and largest Sky Class facility, which is currently under construction

in Medicine Hat, Alberta. To support rapidly growing global demand for high-quality medical cannabis in Canada and abroad, the

facility will be expanded to 1.62 million square feet, representing a 33% increase from its originally planned 1.2 million square

feet. With the Sky Class production philosophy proven at Aurora Sky, the Company is confident in projecting an expected production

capacity at Aurora Sun in excess of 230,000 kg of high-quality cannabis per annum.

Aurora's Sky Class facilities are the most

technologically advanced in the world. They are not greenhouses, but purpose-built, indoor cannabis grow facilities that create

the most optimal growing conditions for cannabis. A sophisticated glass roof, rainwater and snow melt recapture system, and a high-level

of technology and automation give Aurora full control over all anticipated environmental and harvest conditions, resulting in the

production of consistently high yielding, high-quality cannabis at low-cost.

"Aurora Sun represents the next evolution

in our Sky Class facility design, delivering massive scale, low cost production, and consistent, high-quality cannabis," said

Terry Booth, CEO of Aurora. "Particularly in newly-opened markets, establishing first-mover position and embedding Aurora's

market share and brand requires a stable and reliable supply of high-quality cannabis for these markets. The increased scale of

Aurora Sun reflects our expectations for the long-term growth in global demand, especially the higher margin international medical

markets which will be faced with significant supply shortages for the foreseeable future. Sun is also designed with flexibility

in mind to enable us to quickly meet changing market demands, particularly as breeding and cultivation technologies evolve and

as customer preferences and requirements change."

Aurora Sun Facility, Medicine Hat, Alberta (CNW Group/Aurora Cannabis Inc.)

Aurora Sun Facility Highlights:

37 growing rooms, each at 32,500 square feet

At full operation, there will be more than 1,000,000 plants

in various stages of growth in the facility at any given time

Increased automation through next generation robotic shuttles

to mobilize benches, increasing operational speed and facility efficiency, while allowing for multiple product streams simultaneously

Expanded and upgraded facility automation systems for cloning

and production, further lowering anticipated production costs

Next generation, low maintenance climate management system

for superior plant health, yield and cannabinoid potency

Upgraded weather readiness design to drive even greater

operating efficiencies

Additional energy efficiency/energy management via improved

implementation of thermal screens

Improved GMP/GACP segregation between grow, harvest, and

post-production to facilitate faster and most efficient work flow

Higher throughput post-harvesting systems, including drying

systems, to reduce product time to market

Ground work at the facility is nearing completion,

erection of the steel structure is advancing and installation of the glass at Sun is expected to be completed in May 2019. Like

Aurora Sky, Health Canada licensing requests have determined that rooms will be available for planting before the entire facility

of Aurora Sun, March 2019 (CNW Group/Aurora Cannabis Inc.)

Aurora Sun will be even more technologically

advanced than Aurora Sky in a number of ways, including process and technological upgrades that are aimed to increase economic

efficiencies and customer-driven flexibility to meet future evolutions in market requirements. While Aurora Sky integrates

certain post harvest processing systems, Aurora Sun will be focused solely on the mass scale, hyper-efficient production of high-quality

cannabis. Most post-harvest processing will be handled at other facilities, such as Aurora Polaris, the Company's logistics and

derivatives production hub at the Edmonton International Airport (see announcement February 12, 2019).

Headquartered in Edmonton, Alberta, Canada

with funded capacity in excess of 625,000 kg per annum and sales and operations in 24 countries across five continents, Aurora

is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across

every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis

and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

Highly differentiated from its peers, Aurora

has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate

leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale

production of high quality product at low cost. Intended to be replicable and scalable globally, our production facilities are

designed to produce cannabis of significant scale, with high quality, industry-leading yields, and low per gram production costs.

Each of Aurora's facilities is built to meet EU GMP standards, and its first production facility, the recently acquired MedReleaf

Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland have achieved this level of certification.

In addition to the Company's rapid organic

growth and strong execution on strategic M&A, which to date includes 15 wholly owned subsidiary companies - MedReleaf,

CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses,

CanniMed Therapeutics, Anandia Labs, HotHouse Consulting, MED Colombia, Agropro, Borela, and ICC Labs - Aurora is distinguished

by its reputation as a partner and employer of choice in the global cannabis sector, having invested in and established strategic

partnerships with a range of leading innovators, including: Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV:

HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Capcium Inc. (private),

Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), Alcanna Inc. (TSX: CLIQ) and High Tide Inc.

Aurora's Common Shares trade on the TSX and

NYSE under the symbol "ACB", and are a constituent of the S&P/TSX Composite Index.

For more information about Aurora, please visit

our investor website, investor.auroramj.com

Neither the TSX, NYSE nor their Regulation

Services Provider (as that term is defined in the policies of the TSX and NYSE) accepts responsibility for the adequacy or accuracy

Aurora Cannabis Inc.

Forward-Looking Statements

This news release includes statements containing

certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements").

Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect",

"project", "intend", "believe", "anticipate", "estimate", "may", "will",

"potential", "proposed" and other similar words, or statements that certain events or conditions "may"

or "will" occur. Forward looking statements made in this release include: (i) statements regarding the completion

of the facility, (ii) facility characteristics including its size, and cultivation capacity; (ii) statements regarding the rapid

growth of international markets, Aurora's intention to supply those markets, and Aurora's intention to use products grown at Aurora

Sun to supply those markets and the Canadian marketplace; and (iii) information regarding key metrics including predicted production

costs. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections

contained in the forward-looking statements throughout this news release. Certain of the assumptions relied upon include: (i) that

the facility as permitted and constructed will meet the design characteristics described in this news release, (ii) that international

markets for cannabis will continue to grow, and Aurora will be able to obtain necessary licenses and permits not only for the Aurora

Sun facility, but to be able to sell its products in such international markets; and (iii) that the facility will perform in line

with Aurora's past practices and expected design parameters.Forward-looking statements are based on the opinions and estimates

of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that

could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is